Non-invasive Assessment of Fulminant Liver Injury with Contrast-Enhanced Micro CT in Mice Models

doi:10.3969/j.issn.1674-5817.2016.03.004

Abstract

Abstract: Objective To explore the potential use and mechanism of MicroCT using ExiTron nano6000 in the assessment of fulminant liver injury in mouse models. Methods Five male C57BL/6 mice were subjected to administration of LPS/D-GalN to develop model of fulminant liver injury. The mice were scanned with MicroCT before the treatment and at 3 h and 6 h after the establishment of liver injury model. The average CT value of liver were analyzed with software for future study. Twenty male mice were divided into 4 groups, 5 mice in each group: Nano 6000 group, the mice were treated with Nano 6000; PBS group, treated with PBS as control; model 3 h group and 6 h group, injected with LPS/D-GalN and sacrificed at 3 h, 6 h after the injection. Pathological damage of the liver were observed by microscope and serum ALT and AST were detected. Results MicroCT with ExiTron nano6000 as contrast agent could provided specific and clear 2 dimensions and 3 dimensions structure of liver and spleen in mice. The average CT value of liver was significantly increased at 3 h after LPS/D-GalN treatment and drop to baseline level at 6 h. In vitro experiments showed that LPS stimulation could enhance the endocytotic ability of macrophages to uptake ExiTron nano6000. Conclusions The Micro CT provided a rapid noninvasive longitudinal monitoring of fulminant liver injury in mice models and may be had good application in future research.

Key words: Fulminant liver injury, Micro CT, ExiTron nano 6000, Macrophage, Mice

CLC Number:

Q95-33

LI Da-wei, HUA Xiang-wei, ZHANG Jiang, YAO Ju-fang, DAI Hui-li, Kong Xian-ming. Non-invasive Assessment of Fulminant Liver Injury with Contrast-Enhanced Micro CT in Mice Models[J]. Laboratory Animal and Comparative Medicine, 2016, 36(3): 180-185.

References

[1] Younis BB, Arshad R, Khurhsid S, et al.Fulminant hepatic failure (FHF) due to acute hepatitis C[J]. Pak J Med Sci, 2015, 31(4):1009-1011.
[2] Kirnap M, Akdur A, Ozcay F, et al.Liver transplant for fulminant hepatic failure: a single-center experience[J]. Exp Clin Transplant, 2015, 13(4):339-343.
[3] Stadelmann VA, Potapova I, Camenisch K, et al.In vivo microCT monitoring of osteomyelitis in a rat model[J]. Biomed Res Int, 2015, 2015:587857.
[4] Lalwani K, Giddabasappa A, Li D, et al.Contrast agents for quantitative microCT of lung tumors in mice[J]. Comp Med, 2013, 63(6):482-490.
[5] Thurman JM, Rohrer B.Noninvasive detection of complement activation through radiologic imaging[J]. Adv Exp Med Biol, 2013, 735:271-282.
[6] Saito S, Murase K.Detection and early phase assessment of radiation-induced lung injury in mice using micro-CT[J]. PLoS One, 2012, 7(9):e45960.
[7] Wang X, Hagemeyer CE, Hohmann JD, et al.Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice[J]. Circulation, 2012, 125(25):3117-3126.
[8] Kuroda H, Kakisaka K, Kamiyama N, et al.Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude[J]. World J Gastroenterol, 2012, 18(29):3889-3895.
[9] Hyafil F, Cornily JC, Feig JE, et al.Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography[J]. Nat Med, 2007, 13(5):636-641.
[10] Weichert JP, Longino MA, Bakan DA, et al.Polyiodinated triglyceride analogs as potential computed tomography imaging agents for the liver[J]. J Med Chem, 1995, 38(4):636-646.
[11] Bakan DA, Doerr-Stevens JK, Weichert JP, et al.Imaging efficacy of a hepatocyte-selective polyiodinated triglyceride for contrast-enhanced computed tomography[J]. Am J Ther, 2001, 8(5):359-365.
[12] Willekens I, Lahoutte T, Buls N, et al.Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC[J]. Mol Imaging Biol, 2009, 11(2):128-135.
[13] Boll H, Figueiredo G, Fiebig T, et al.Com〈parison of Fenestra LC, ExiTron nano 6000, and ExiTron nano 12000 for micro-CT imaging of liver and spleen in mice[J]. Acad Radiol, 2013, 20(9):1137-1143.
[14] Ding J, Wang Y, Ma M, et al.CT/fluorescence dual-modal nanoemulsion platform for investigating atherosclerotic plaques[J]. Biomaterials, 2013, 34(1):209-216.
[15] Chen W, Vucic E, Leupold E, et al.Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis[J]. Contrast Media Mol Imaging, 2008, 3(6): 233-242.
[16] Liu LM, Zhang JX, Luo J, et al.A role of cell apoptosis in lipopolysaccharide (LPS)-induced nonlethal liver injury in D-galactosamine (D-GalN)-sensitized rats[J]. Dig Dis Sci, 2008, 53(5):1316-1324.
[17] Zhang S, Yang N, Ni S, et al.Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway[J]. Int J Clin Exp Pathol, 2014, 7(10):6626-6634.
[18] Chastre A, Belanger M, Beauchesne E, et al.Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications[J]. PLoS One, 2012, 7(11):e49670.
[19] Inoue K, Takano H, Satoh M.Protective role of metallothionein in coagulatory disturbance accompanied by acute liver injury induced by LPS/D-GalN[J]. Thromb Haemost, 2008, 99(5):980-983.
[20] Ahmad A, Raish M, Ganaie MA, et al.Hepatoprotective effect of Commiphora myrrha against d-GalN/LPS-induced hepatic injury in a rat model through attenuation of pro inflammatory cytokines and related genes[J]. Pharm Biol, 2015, 53(12):1759-1767.
[21] Liu H, Zhang W, Dong S, et al.Protective effects of Sea buckthorn polysaccharide extracts against LPS/d-GalN-induced acute liver failure in mice via suppressing TLR4-NF-kappaB signaling[J]. J Ethnopharmacol, 2015, 176:69-78.
[22] Streetz K, Leifeld L, Grundmann D, et al.Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure[J]. Gastroenterology, 2000, 119(2):446-460.